Neratinib plus fulvestrant and eribulin after trastuzumab deruxtecan in HR+/HER2+ advanced breast cancer: A single-arm, multicenter exploratory study

Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca

Nerlynx (neratinib) - Puma

Halaven (eribulin mesylate) - Eisai

fulvestrant - Generic mfg.

L. wang1; J. Wu2; F. Cui2; Y. Yang2; J. Yang2; J. Yu2; S. Li2; N. Li3

Feb 25, 2026